Freedom of Information Request – Ref: FOI 237-2022
Thank you for your recent Freedom of Information request. Please find our response below:
Q1. In the past 3 months or the latest 3 months data you have available., how many melanoma patients were treated with:
Bevacizumab Avastin.
Dacarbazine DTIC.
Trametinib Mekinist.
Dabrafenib Tafinlar.
Ipilimumab Yervoy.
Vemurafenib Zelboraf.
Nivolumab Opdivo.
Nivolumab + Ipilimumab Opdivo + Yervoy.
Pembrolizumab Keytruda.
Vemurafenib + cobimetinib Zelboraf + Cotellic.
Dabrafenib + Trametinib Tafinlar + Mekinist.
Braftovi encorafenib. in combination with Mektovi binimetinib. for BRAF V600 patients
Other active systemic anti-cancer therapy [please state]
Palliative care only
Q2. In the past 3 months or the latest 3 months data you have available., how many metastatic melanoma patients were treated with the following:
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Dabrafenib AND Trametinib
Any Other Targeted Therapy Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib.
Other active systemic anti-cancer therapy
Palliative care only
We would answer ‘zero’ to all these questions. Diagnosis and prescribing for melanoma would not happen in GHC